Compared side by side
Tirzepatide vs dulaglutide: how they differ
The short answer
Dulaglutide activates one receptor, GLP-1; tirzepatide activates GLP-1 and GIP. Both are weekly shots with half-lives of about 5 days, and both are FDA-approved for type 2 diabetes, dulaglutide as Trulicity and tirzepatide as Mounjaro; only tirzepatide is approved for weight management, as Zepbound. Dulaglutide’s effect on weight is modest, about 1 to 5 kg on average in its diabetes trials, and tirzepatide’s 15 mg produced up to 22.5% weight loss at 72 weeks (SURMOUNT-1).
Side by side
| Compared | Tirzepatide | Dulaglutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Mounjaro, Zepbound, LY3298176 | Trulicity, LY2189265, Dula |
| What it is | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). | A weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens. |
| How it works | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. | GLP-1 receptor agonist made as a fusion protein: two GLP-1 analogue chains, 90% the same as human GLP-1, joined to the Fc fragment of a modified IgG4 antibody (about 63 kDa). It releases insulin when glucose is high, lowers glucagon and slows stomach emptying. Its large Fc-fusion design slows its clearance, to a half-life of about 5 days, which makes it a weekly shot. FDA-approved in 2014 for type 2 diabetes (adults, and children 10 and older) and to lower major cardiovascular events in adults with type 2 diabetes and heart disease or its risk factors; it is not approved for weight management. |
| Commonly reported | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). | Steadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it. |
| Studied range | FDA label: 2.5–15 mg, starting dose 2.5 mg. | FDA label: 0.75–4.5 mg, starting dose 0.75 mg. |
| How often | Weekly | Weekly |
| Half-life | ~5 days (FDA label) | ~5 days (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. | FDA-approved for ongoing use; its heart-outcomes trial followed people for a median of 5.4 years. The 3 and 4.5 mg steps are optional, for more glucose control. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue |
- Category
- TirzepatideMetabolic & GLP-1
- DulaglutideMetabolic & GLP-1
- Also known as
- TirzepatideMounjaro, Zepbound, LY3298176
- DulaglutideTrulicity, LY2189265, Dula
- What it is
- TirzepatideThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
- DulaglutideA weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens.
- How it works
- TirzepatideDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
- DulaglutideGLP-1 receptor agonist made as a fusion protein: two GLP-1 analogue chains, 90% the same as human GLP-1, joined to the Fc fragment of a modified IgG4 antibody (about 63 kDa). It releases insulin when glucose is high, lowers glucagon and slows stomach emptying. Its large Fc-fusion design slows its clearance, to a half-life of about 5 days, which makes it a weekly shot. FDA-approved in 2014 for type 2 diabetes (adults, and children 10 and older) and to lower major cardiovascular events in adults with type 2 diabetes and heart disease or its risk factors; it is not approved for weight management.
- Commonly reported
- TirzepatideVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
- DulaglutideSteadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it.
- Studied range
- TirzepatideFDA label: 2.5–15 mg, starting dose 2.5 mg.
- DulaglutideFDA label: 0.75–4.5 mg, starting dose 0.75 mg.
- How often
- TirzepatideWeekly
- DulaglutideWeekly
- Half-life
- Tirzepatide~5 days (FDA label)
- Dulaglutide~5 days (FDA label)
- Route
- TirzepatideSubQ injection
- DulaglutideSubQ injection
- Typical run
- TirzepatideFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
- DulaglutideFDA-approved for ongoing use; its heart-outcomes trial followed people for a median of 5.4 years. The 3 and 4.5 mg steps are optional, for more glucose control.
- Evidence
- TirzepatideEstablished: clinical trials or FDA-approved use exists
- DulaglutideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- TirzepatideNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue
- DulaglutideNausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Tirzepatide
- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course
Dulaglutide
- Day 1–28 · 0.75 mg The 0.75 mg start
- Day 29–364 · 1.5 mg 1.5 mg, the dose of its heart trial
- Day 57–364 · 3 mg 3 mg, a step for more glucose control
- Day 85–364 · 4.5 mg 4.5 mg, the top dose
- Day 365+ A long-term medicine, not a course
Questions people ask
How long do tirzepatide and dulaglutide last?
The half-life of tirzepatide is ~5 days (FDA label). The half-life of dulaglutide is ~5 days (FDA label).
How often are tirzepatide and dulaglutide taken?
Tirzepatide: weekly. Route: SubQ injection. Dulaglutide: weekly. Route: SubQ injection.
How are tirzepatide and dulaglutide dosed in research?
The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The FDA label range for dulaglutide is 0.75–4.5 mg, with a 0.75 mg starting dose.
What are the common side effects of tirzepatide and dulaglutide?
For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For dulaglutide: nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion, fatigue.